ATE380551T1 - Verwendung von brimonidine zur behandlung von dementia und morbus parkinson - Google Patents
Verwendung von brimonidine zur behandlung von dementia und morbus parkinsonInfo
- Publication number
- ATE380551T1 ATE380551T1 AT03773199T AT03773199T ATE380551T1 AT E380551 T1 ATE380551 T1 AT E380551T1 AT 03773199 T AT03773199 T AT 03773199T AT 03773199 T AT03773199 T AT 03773199T AT E380551 T1 ATE380551 T1 AT E380551T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- parkinson
- brimonidine
- treat dementia
- dementia
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 title 1
- 206010012289 Dementia Diseases 0.000 title 1
- 229960003679 brimonidine Drugs 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000000979 retarding effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41703102P | 2002-10-08 | 2002-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE380551T1 true ATE380551T1 (de) | 2007-12-15 |
Family
ID=32093952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03773199T ATE380551T1 (de) | 2002-10-08 | 2003-10-07 | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20040116436A1 (https=) |
| EP (1) | EP1549314B1 (https=) |
| JP (1) | JP2006504741A (https=) |
| KR (1) | KR20050056235A (https=) |
| CN (1) | CN100370988C (https=) |
| AT (1) | ATE380551T1 (https=) |
| AU (2) | AU2003279874A1 (https=) |
| BR (1) | BR0314541A (https=) |
| CA (1) | CA2501348A1 (https=) |
| DE (1) | DE60318081T2 (https=) |
| ES (1) | ES2297233T3 (https=) |
| HK (1) | HK1080408B (https=) |
| IL (1) | IL167848A (https=) |
| MX (1) | MXPA05003665A (https=) |
| NO (1) | NO20051664L (https=) |
| NZ (1) | NZ539329A (https=) |
| PL (1) | PL376347A1 (https=) |
| RU (1) | RU2332218C2 (https=) |
| WO (1) | WO2004032934A1 (https=) |
| ZA (1) | ZA200502745B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7512436B2 (en) * | 2004-02-12 | 2009-03-31 | The Regents Of The University Of Michigan | Method of evaluating metabolism of the eye |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US20100298305A1 (en) * | 2008-11-26 | 2010-11-25 | The United States Government, As Represented By The Department Of Veterans Affairs | Tizanidine for the treatment of post-traumatic stress disorder and nightmares |
| DE102009043750A1 (de) * | 2009-09-30 | 2011-08-04 | Carl Zeiss Meditec AG, 07745 | Verfahren und Vorrichtung zur Detektion von Ablagerungen im Auge |
| WO2016089997A1 (en) * | 2014-12-02 | 2016-06-09 | Yale University | Methods of preventing neurodegeneration of association cortex in a mammal |
| RU2680526C1 (ru) * | 2016-07-05 | 2019-02-22 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Нейропротекторное средство, обладающее свойствами антиоксиданта и донатора оксида азота |
| US20210282643A1 (en) * | 2016-08-01 | 2021-09-16 | Cognoptix, Inc. | System And Method For Detecting Tau Protein In Ocular Tissue |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4029792A (en) * | 1972-02-29 | 1977-06-14 | Pfizer Inc. | (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents |
| BE795970A (fr) * | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
| US5210076A (en) * | 1988-09-13 | 1993-05-11 | Berliner David L | Methods of treating Parkinson's disease using melanin |
| MX9709112A (es) * | 1995-05-26 | 1998-02-28 | Pfizer | Combinacion para el tratamiento de parkinsonismo que contienen antagonistas selectivos de n-metil-d-aspartato. |
| US6194415B1 (en) * | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| JP4783502B2 (ja) * | 1997-12-04 | 2011-09-28 | アラーガン、インコーポレイテッド | α２Ｂまたは２Ｂ／２Ｃアドレナリン受容体において作動剤様活性を示す置換イミダゾール誘導体 |
| US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| US6329369B1 (en) * | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
| US6313172B1 (en) * | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
| PL360707A1 (en) * | 2000-07-14 | 2004-09-20 | Allergan Inc. | Compositions containing alpha-2-adrenergic agonist components |
-
2003
- 2003-10-07 JP JP2004543508A patent/JP2006504741A/ja active Pending
- 2003-10-07 PL PL03376347A patent/PL376347A1/xx not_active Application Discontinuation
- 2003-10-07 HK HK06100172.4A patent/HK1080408B/en not_active IP Right Cessation
- 2003-10-07 CN CNB2003801011164A patent/CN100370988C/zh not_active Expired - Fee Related
- 2003-10-07 KR KR1020057006115A patent/KR20050056235A/ko not_active Ceased
- 2003-10-07 DE DE60318081T patent/DE60318081T2/de not_active Expired - Lifetime
- 2003-10-07 US US10/680,996 patent/US20040116436A1/en not_active Abandoned
- 2003-10-07 ES ES03773199T patent/ES2297233T3/es not_active Expired - Lifetime
- 2003-10-07 BR BR0314541-7A patent/BR0314541A/pt not_active IP Right Cessation
- 2003-10-07 WO PCT/US2003/031842 patent/WO2004032934A1/en not_active Ceased
- 2003-10-07 AU AU2003279874A patent/AU2003279874A1/en not_active Abandoned
- 2003-10-07 AT AT03773199T patent/ATE380551T1/de not_active IP Right Cessation
- 2003-10-07 EP EP03773199A patent/EP1549314B1/en not_active Expired - Lifetime
- 2003-10-07 MX MXPA05003665A patent/MXPA05003665A/es active IP Right Grant
- 2003-10-07 NZ NZ539329A patent/NZ539329A/en not_active IP Right Cessation
- 2003-10-07 RU RU2005114505/14A patent/RU2332218C2/ru not_active IP Right Cessation
- 2003-10-07 CA CA002501348A patent/CA2501348A1/en not_active Abandoned
-
2005
- 2005-04-04 NO NO20051664A patent/NO20051664L/no not_active Application Discontinuation
- 2005-04-04 IL IL167848A patent/IL167848A/en not_active IP Right Cessation
- 2005-04-05 ZA ZA200502745A patent/ZA200502745B/en unknown
-
2010
- 2010-02-26 AU AU2010200730A patent/AU2010200730A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003279874A1 (en) | 2004-05-04 |
| HK1080408B (en) | 2008-08-08 |
| MXPA05003665A (es) | 2005-06-08 |
| ES2297233T3 (es) | 2008-05-01 |
| EP1549314B1 (en) | 2007-12-12 |
| JP2006504741A (ja) | 2006-02-09 |
| RU2332218C2 (ru) | 2008-08-27 |
| WO2004032934A1 (en) | 2004-04-22 |
| AU2010200730A1 (en) | 2010-03-18 |
| CN100370988C (zh) | 2008-02-27 |
| ZA200502745B (en) | 2006-07-26 |
| NZ539329A (en) | 2007-11-30 |
| DE60318081D1 (de) | 2008-01-24 |
| KR20050056235A (ko) | 2005-06-14 |
| PL376347A1 (en) | 2005-12-27 |
| NO20051664L (no) | 2005-05-31 |
| CN1703222A (zh) | 2005-11-30 |
| EP1549314A1 (en) | 2005-07-06 |
| HK1080408A1 (en) | 2006-04-28 |
| US20040116436A1 (en) | 2004-06-17 |
| CA2501348A1 (en) | 2004-04-22 |
| BR0314541A (pt) | 2005-07-26 |
| RU2005114505A (ru) | 2005-10-27 |
| IL167848A (en) | 2010-11-30 |
| DE60318081T2 (de) | 2008-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60132777D1 (de) | Benzothiazolderivate zur behandlung von alzheimer und parkinson | |
| EP1484366A4 (en) | TREATED PIGMENT, USE THEREOF AND COMPOUND FOR TREATING PIGMENTS | |
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| ATE323482T1 (de) | Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten | |
| ATE198044T1 (de) | Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges | |
| MY140132A (en) | Thiazolidin-4-one derivatives for use in the treatment of anemias | |
| DE60325770D1 (de) | Verwendung von rimexolon zur behandlung von augentrockenheit | |
| ATE384699T1 (de) | 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten | |
| ATE336996T1 (de) | Verwendung von flavonoid-derivaten zur behandlung von atopischem ekzem | |
| ATE435026T1 (de) | Verfahren zur prävention und behandlung von diabetes mit neurturin | |
| ATE383853T1 (de) | Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit | |
| ATE380551T1 (de) | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson | |
| ATE289196T1 (de) | Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen | |
| ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
| ATE294584T1 (de) | Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz | |
| ATE425967T1 (de) | Piperazin und piperadin-derivate fur die behandlung von neurologischen krankheiten | |
| ATE334124T1 (de) | Chinolinderivate, herstellungsprozess und verwendung zur behandlung von krankheiten, bei den s-cd23 involviert ist | |
| DE60028538D1 (de) | Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen | |
| EP4277624C0 (en) | TRORILUZOLE FOR THE TREATMENT OF MILD ALZHEIMER'S DISEASE | |
| ATE390134T1 (de) | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen | |
| DE602005015697D1 (de) | Te zur behandlung von alzheimer-krankheit | |
| DE60327335D1 (de) | Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson | |
| ATE448779T1 (de) | Methode zur behandlung trockener augen und uveitis | |
| ATE482217T1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |